Akebia: Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

In This Article: CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024 at 7:30 AM PST . Among other business updates, Mr. Butler will discuss the Vafseo® (vadadustat) U.S. launch. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.) A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. The J.P. Morgan Healthcare Conference will take place January 13-16, 2025 in San Francisco . About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release. Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@akebia.com Cision